Proteins and Peptides

24 June 2015

CSL Behring Announces Pivotal Data of Novel rVIII-SingleChain Therapy in Adolescents and Adults with Hemophilia A

23 June 2015

Zosano Pharma Completes Enrollment in Phase 2 Trial for ZP-Glucagon, Its Microneedle Patch for Treatment of Severe Hypoglycemia

23 June 2015

Synergy Pharmaceuticals Initiates Second Phase 3 Clinical Trial of Plecanatide in Patients with Irritable Bowel Syndrome with Constipation

22 June 2015

Portola, Bristol-Myers Squibb and Pfizer Announce Full Results of Second Part of Phase 3 ANNEXA-A™ Study Demonstrating that Investigational Andexanet Alfa Sustained Reversal of Anticoagulant Effect of Factor Xa Inhibitor Eliquis (apixaban)

19 June 2015

Baxalta Demonstrates Commitment to Innovation in Hemophilia and Blood Disorders at ISTH 2015 Congress

19 June 2015

Sandoz announces US launch of Glatopa(TM), the first generic competitor to Copaxone® 20mg

18 June 2015

Admune Announces the First-in-Human Study of Heterodimeric IL-15 (hetIL-15) with Broad Applications for Cancer Immunotherapy

18 June 2015

Derma Sciences Completes Non-Clinical Aclerastide Toxicology Program

18 June 2015

Radius Announces Positive Top-Line Data From ACTIVExtend Trial Including Combined 25 Month Results

18 June 2015

Viventia Presents Validating Evidence for Highly Differentiated De-immunized Payload for Oncology at 13th Empowered Antibodies Conference

18 June 2015

BMN 111 (vosoritide) Improves Growth Velocity in Children With Achondroplasia in Phase 2 Study

17 June 2015

Synergy Pharmaceuticals Announces Positive Results in the First Phase 3 Trial of Plecanatide in Patients with Chronic Idiopathic Constipation (CIC)

15 June 2015

Chiasma Submits New Drug Application to U.S. FDA for Octreotide Capsules in Acromegaly

15 June 2015

Genzyme Initiates Phase 1/2 Clinical Trial to Evaluate Olipudase Alfa in Pediatric Patients

10 June 2015

Pieris Pharmaceuticals Completes Dosing of Healthy Volunteers in Phase I Clinical Trial for Anticalin Program in Anemia

10 June 2015

Immune Pharmaceuticals Expands Immuno-Dermatology Development Portfolio With Topical Nano-Formulated Cyclosporine A

8 June 2015

Sanofi’s Lyxumia® (lixisenatide) Demonstrated Cardiovascular Safety in People with Type 2 Diabetes and High CV Risk

8 June 2015

AntriaBio Announces Promising Preclinical Results for Once-Weekly Basal Insulin AB101

8 June 2015

Ultragenyx Announces Completion of Enrollment in Phase 3 Study of Recombinant Human Beta-Glucuronidase in Mucopolysaccharidosis Type 7

8 June 2015

Intarcia Announces Presentations At ADA Of Two Successful FREEDOM Phase 3 Trials For ITCA 650 — A GLP-1 RA For Type 2 Diabetes

8 June 2015

Hanmi Pharmaceutical: Efpeglenatide (GLP-1 Analog), the Promising Potential for Anti-Diabetes/Anti-Obesity Treatment as Once Weekly up to Once Monthly

8 June 2015

PhaseBio Pharmaceuticals Announces Positive Data for Type 2 Diabetes Treatments PE0139 and PB1023

8 June 2015

Hanmi Pharmaceutical : Once-Weekly Insulin Combination, ‘LAPSInsulin Combo’, Suggests a New Diabetes Therapeutic Option

8 June 2015

Lilly’s Basal Insulin Peglispro Shows Superiority to Insulin Glargine in Reducing HbA1c in People with Type 2 Diabetes

8 June 2015

Basal Insulin Peglispro Studies Demonstrate Superiority to Insulin Glargine Across Multiple Measures in People with Type 1 Diabetes

8 June 2015

New Xultophy® (IDegLira) Phase 3b Study Showed Statistically Significant HbA1c Reduction, Body Weight Change and Lower Rate of Hypoglycaemia Versus Insulin Glargine

8 June 2015

Sanofi Announces Positive Results for Toujeo® in Phase III Study Extension in Japanese People with Uncontrolled Diabetes

8 June 2015

Presentations on two novel Zealand preclinical peptide therapeutics as possible approaches for the treatment of Type 2 diabetes and obesity at the American Diabetes Association’s (ADA) 74th Scientific Sessions

6 June 2015

Sanofi’s Lyxumia® (lixisenatide) Statistically Superior to Rapid Acting Insulin for Body Weight Change with Similar Blood Sugar Control when Both are Added to Basal Insulin

5 June 2015

Horizon Pharma plc Initiates Phase 3 Trial of ACTIMMUNE(R) (interferon gamma-1b) for the Treatment of People With Friedreich’s Ataxia

News Channels

Newsletter

La Merie Biologics

La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.

Newsletter La Merie Biologics

Newsletter

New Product Alert

La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.

Newsletter new product alert

Featured reports

Claudin 6: A target opportunity to develop effector-enhanced drug modalities

CD38-Targeted Antibody & Cell Therapy Pipeline Review

Bispecific Antibodies for Immuno-Oncology & Other Diseases

Biologics Sales Database for Antibodies, Proteins, Biosimilars, Gene & Cell Therapy and RNA

Nectin-4-Targeted Immunotherapy Pipeline Review

Pembrolizumab (Keytruda) Biosimilar Antibody Pipeline Review

Claudin 6, Cadherin 17, ROR1 and GPRC5D-Targeted Therapies: Target Expression Profile, Safety & Efficacy of Drug Modalities, Pipeline Review, and Competitive Landscape Analysis

GPC3-Targeted Immunotherapy Pipeline Review

Adalimumab (Humira) Biosimilars Pipeline Review

B7-H4 Targeted Antibody Therapy Pipeline Review